Exciting News! Enlil has partnered with OVA Solutions to tackle one of MedTech’s biggest and most preventable challenges: the costly gap between product development and compliance documentation. This issue can lead to losses of $100K–$200K and months of program delays, often before products even reach the FDA. By joining forces, Enlil’s AI-powered traceability platform and OVA Solutions’ medical device engineering expertise are directly addressing the “build first, document later” pattern. Did you know that even an undocumented $14 part change can result in $180K in rework and four months of delay? Our alliance aims to eliminate these setbacks, helping teams bridge the gap between design, documentation, and regulatory readiness. As Nader Fathi, CEO of Enlil, puts it: “MedTech innovators are under constant pressure to move faster without sacrificing compliance or product quality. Our alliance with OVA Solutions brings together Enlil’s intelligent, purpose-built traceability platform and OVA’s deep engineering capability to help teams create a more seamless bridge between product design, documentation, and regulatory readiness — so promising technologies don’t get stuck in process drag.” Device makers who treat documentation as an afterthought face a tougher regulatory environment and unexpected delays. Programs with complete, traceable design histories move faster and experience fewer surprises, while those without must pay the price of reconstruction. By solving this at the system level, Enlil and OVA Solutions help teams accelerate innovation and streamline regulatory approval. Connect with us to learn how this alliance can empower your next breakthrough. #Enlil #OvaSolutions #Strategicalliance #News #MedTech #MedTechRegulatoryReadiness #FDAQMSRcompliance #medicaldesignengineering #medicaldesigntracability

Exciting News! Enlil has partnered with OVA Solutions to tackle one of MedTech’s biggest and most preventable challenges: the costly gap between product development and compliance documentation. This issue can lead to losses of $100K–$200K and months of program delays, often before products even reach the FDA. By joining forces, Enlil’s AI-powered traceability platform and OVA Solutions’ medical device engineering expertise are directly addressing the “build first, document later” pattern. Did you know that even an undocumented $14 part change can result in $180K in rework and four months of delay? Our alliance aims to eliminate these setbacks, helping teams bridge the gap between design, documentation, and regulatory readiness. As Nader Fathi, CEO of Enlil, puts it: “MedTech innovators are under constant pressure to move faster without sacrificing compliance or product quality. Our alliance with OVA Solutions brings together Enlil’s intelligent, purpose-built traceability platform and OVA’s deep engineering capability to help teams create a more seamless bridge between product design, documentation, and regulatory readiness — so promising technologies don’t get stuck in process drag.” Device makers who treat documentation as an afterthought face a tougher regulatory environment and unexpected delays. Programs with complete, traceable design histories move faster and experience fewer surprises, while those without must pay the price of reconstruction. By solving this at the system level, Enlil and OVA Solutions help teams accelerate innovation and streamline regulatory approval. Connect with us to learn how this alliance can empower your next breakthrough. #Enlil #OvaSolutions #Strategicalliance #News #MedTech #MedTechRegulatoryReadiness #FDAQMSRcompliance #medicaldesignengineering #medicaldesigntracability